Rituximab Effective for Autoimmune Retinopathy
American Journal of Ophthalmology, August 2017
Davoudi et al. set out to report outcomes for patients with autoimmune retinopathy (AIR) treated with rituximab as well as to evaluate whether adaptive optics scanning laser ophthalmoscopy (AO-SLO) is an effective monitoring tool for these patients. They found that visual acuity (VA) either improved or stabilized in the majority of the patients. They also found that AO-SLO findings remained stable during treatment; however, these results did not reach statistical significance.
For this retrospective case series, the investigators evaluated data on 16 AIR patients (30 eyes) who were examined at 1 center during 2010-2016. All were treated with a loading and maintenance dose of rituximab. In addition, all patients received ancillary testing, including electroretinograms (ERGs), visual fields, and spectral-domain optical coherence tomography (SD-OCT). A subset of patients (n = 4) had AO-SLO images that could be analyzed.
For the primary outcome, VA improved in 2 patients, stabilized in 11, and declined in 3. The variances may reflect the point in the disease course during which treatment was initiated, the authors said, as the 2 patients who experienced improvement started rituximab early on during their disease. ERG and SD-OCT parameters as well as AO-SLO cone densities were stable during treatment.
The authors noted that larger studies with longer follow-up are needed to prospectively assess the effectiveness of rituximab and the use of AO-SLO to monitor disease progression.
The original article can be found here.